Although ovarian cancer has low response to checkpoint inhibitors, IL2 has shown clinical promise in platinum-resistant and refractory disease.[2] The IL2-pathway agonist NKTR-214 activates and mobilizes CD8T and NK cells to tumor in human and mouse via the IL2Rβγ complex. Here, IL2 is linked to ovarian carcinoma.